Trial Profile
Phase II Study of Intrapleural Administration of Bevacizumab Versus Recombinant Human Endostatin (Endostar) for Refractory Malignant Pleural Effusions in Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Endostatin (Primary)
- Indications Malignant pleural effusion; Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Dec 2013 New trial record
- 01 Dec 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.